Try our Advanced Search for more refined results
Life Sciences
- 
									September 22, 2025
									J&J Ruling Misapplied Goldman Precedent, 3rd Circ. ToldThe U.S. Chamber of Commerce and other business organizations are supporting Johnson & Johnson's call for the full Third Circuit to reconsider a ruling that the groups argue could "saddle" companies with investor class-action suits through the misapplication of a recent U.S. Supreme Court ruling. 
- 
									September 22, 2025
									Catching Up With Delaware's Chancery CourtLast week, Match.com secured approval for a $30M settlement over its 2019 reverse spinoff from IAC, and Vice Chancellor Morgan T. Zurn urged decorum among Delaware lawyers, comparing recent legal turmoil to dark times in British monarchy history. Here's the latest from the Chancery Court. 
- 
									September 22, 2025
									CVS's Omnicare Hits Ch. 11 After $949M FCA JudgmentOmnicare LLC, CVS Health's subsidiary that provides pharmacy services for long-term care facilities, filed for Chapter 11 bankruptcy relief Monday in Texas following a $949 million judgment against Omnicare and CVS issued by a New York federal judge earlier this year. 
- 
									September 22, 2025
									Wachtell, Paul Weiss Advise On Pfizer's $7.3B Obesity PathPfizer Inc. will acquire Metsera Inc. for $4.9 billion in cash, as the U.S. pharmaceutical giant bets on the biotech firm's experimental treatments for obesity and cardiometabolic diseases, the companies said Monday. 
- 
									September 22, 2025
									ProPhase COVID-19 Testing Units Hit Ch. 11 In NJBiotechnology company ProPhase Labs Inc. put three of its COVID-19 laboratory testing subsidiaries in Chapter 11 bankruptcy Monday in New Jersey with combined liabilities of more than $13 million, saying it has been underpaid by insurance companies. 
- 
									September 21, 2025
									Chinese Exec Who Shipped Fentanyl Ingredients Gets 25 YrsA Manhattan federal judge on Friday sentenced a Chinese national and chemical company executive to 25 years in prison for shipping large quantities of fentanyl ingredients to the U.S., citing the defendant's "egregious, callous" disregard for the deaths caused by the drugs he helped create. 
- 
									September 19, 2025
									Stewart Issues Mixed Bag Of Referrals, Denied PetitionsCoke Morgan Stewart issued some of her final decisions as acting director of the U.S. Patent and Trademark Office, discretionarily denying a host of petitions for Patent Trial and Appeal Board review, while also referring a group of Apple Inc.'s petitions to the board for scrutiny. 
- 
									September 19, 2025
									Call For Gov't Cut Of University Patent Cash Spurs ConcernCommerce Secretary Howard Lutnick's comments that the government should get as much as half of the revenue that universities generate from patents developed with federal funding have caused worry among industry groups and attorneys, who say it would inhibit efforts to commercialize publicly funded inventions. 
- 
									September 19, 2025
									Goodwin, Latham Steer E-Commerce Co. Pattern's $300M IPOTop Amazon.com reseller Pattern Group Inc. kicked off its public-market trading debut on the Nasdaq on Friday with a $300 million initial public offering guided by Goodwin Procter LLP, and Latham & Watkins LLP represented the underwriters, which include Goldman Sachs & Co. LLC and J.P. Morgan. 
- 
									September 19, 2025
									PTAB Invalidates Johns Hopkins Patent In Keytruda FightThe Patent Trial and Appeal Board has invalidated an anti-cancer therapy patent owned by Johns Hopkins University, handing a win to challenger Merck Sharp & Dohme LLC in a larger fight relating to Merck's Keytruda treatment. 
- 
									September 19, 2025
									DA In Gilgo Beach Killings Case Talks Advances In DNA UseLaw360 sat down with Suffolk County, New York, District Attorney Ray Tierney, who is prosecuting architect Rex Heuermann on charges that he murdered seven women on Long Island, to discuss the use of a newer form of DNA testing that has passed rigorous admissibility standards for the first time, among other aspects of the case. 
- 
									September 19, 2025
									Moderna Wants Fed. Circ. Reversal Of Vax Patent InvalidationModerna has told the Federal Circuit that the Patent Trial and Appeal Board got it wrong when it found that the success of the inventions behind two of its COVID-19 vaccine patents challenged by Pfizer and BioNTech didn't outweigh the evidence they were invalid as obvious. 
- 
									September 19, 2025
									Rite Aid Gets OK To Seek Votes On Dual-Track Ch. 11 PlanA New Jersey bankruptcy judge on Friday approved drugstore chain Rite Aid's bid to take votes on a Chapter 11 plan as the debtor weighs whether to complete a deal with McKesson Corp. or formally seek to dismiss its bankruptcy case. 
- 
									September 19, 2025
									CDC Panel Urges Caution On COVID Vax, Punts On Hep BA panel of advisers at the Centers for Disease Control and Prevention on Friday voted unanimously to recommend that people receiving the COVID-19 vaccine this season do so only after discussing it with their health providers. 
- 
									September 18, 2025
									Federal Vaccine Panel Votes To Tweak MMRV RecommendationA panel of federal vaccine advisers on Thursday changed its recommendation for a long-used vaccine for children but allowed a key government program to continue paying for the shots. 
- 
									September 18, 2025
									Cytokinetics Investor Sues Over Heart Drug Approval ClaimsBiopharmaceutical company Cytokinetics and its CEO have been hit with a proposed investor class action in California federal court alleging they made false and misleading statements about the regulatory timeline for one of the company's new drugs, which caused a share price drop when the truth came to light. 
- 
									September 18, 2025
									Brothers Blame Associate For $90M HIV Drug Fraud SchemeTwo Maryland brothers accused of selling $90 million worth of mislabeled HIV drugs told a Florida federal jury on Thursday that their charges stem from an associate hired for his pharmaceutical industry connections, but who instead lied about the medication's black market origins and told them it was purchased legitimately. 
- 
									September 18, 2025
									HHS Shutters Miami Organ Donor Org. For 'Unsafe' PracticesFederal health officials have decertified a Miami-based organ procurement organization that arranges organ donations after an investigation found a pattern of "unsafe" practices, marking the first time the federal government has revoked the certification of such a group, according to an announcement Thursday from Health Secretary Robert F. Kennedy Jr. 
- 
									September 18, 2025
									Senate Confirms Squires To Lead USPTOThe U.S. Senate on Thursday confirmed Dilworth Paxson LLP partner John Squires to serve as the next U.S. Patent and Trademark Office director. 
- 
									September 18, 2025
									Senate Confirms Trump's Pick To Lead DOL Benefits ArmThe Senate confirmed fiduciary liability insurance expert Daniel Aronowitz on Thursday to lead the U.S. Department of Labor's employee benefits division, which oversees regulation and enforcement of employer-provided health and retirement plans. 
- 
									September 18, 2025
									Steptoe Adds Jones Day Biotech Patent Pro To NY OfficeSteptoe LLP has bolstered its intellectual property practice with an attorney arriving from Jones Day with multinational experience advising biotech and biopharmaceutical companies on patent issues. 
- 
									September 18, 2025
									Colibri Wants Full Fed. Circ. To Rethink Medtronic Patent CaseColibri Heart Valve LLC wants the full Federal Circuit to review a panel's ruling overturning a patent infringement judgment of more than $125 million against Medtronic's CoreValve unit, saying the panel wrongly applied a reading of the law that is too broad. 
- 
									September 18, 2025
									NJ City Makes 3rd Escape From Pot Co.'s Zoning SuitFor the third time, a New Jersey federal judge has dismissed claims from a would-be cannabis dispensary alleging the city of Asbury Park and its zoning board conspired to deny its application for a medical marijuana store. 
- 
									September 18, 2025
									Dorsey & Whitney IP Atty Joins Foley Hoag In DenverFoley Hoag LLP announced the addition of its first intellectual property partner in the West with the hire of a longtime Dorsey & Whitney LLP attorney in its fast-growing Denver office. 
- 
									September 18, 2025
									Montreal-Based Corp. Atty Moves To Akerman's NY OfficeAkerman LLP has announced that a former Quebec-based partner at the Canadian business law firm Davies Ward Phillips & Vineberg LLP is returning to New York to join its corporate practice group. 
Expert Analysis
- 
								Series My Opera And Baseball Careers Make Me A Better Lawyer  Though participating in opera and the world of professional baseball often pulls me away from the office, my avocations improve my legal career by helping me perform under scrutiny, prioritize team success, and maintain joy and perspective at work, says Adam Unger at Herrick Feinstein. 
- 
								Opinion Subject Matter Eligibility Test Should Return To Preemption  Subject matter eligibility has posed challenges for patentees due to courts' arbitrary and confusing reasoning, but adopting a two-part preemption test could align the applicant, the U.S. Patent and Trademark Office and the courts, says Manav Das at McDonnell Boehnen. 
- 
								
								8 Ways Lawyers Can Protect The Rule Of Law In Their Work  Whether they are concerned with judicial independence, regulatory predictability or client confidence, lawyers can take specific meaningful actions on their own when traditional structures are too slow or too compromised to respond, says Angeli Patel at the Berkeley Center of Law and Business. 
- 
								
								Is SEC Moving Away From Parallel Insider Trading Cases?  The U.S. Securities and Exchange Commission's apparent lack of follow-up in four recent criminal cases of insider trading brought by the Justice Department suggests the SEC may be reconsidering the expense and effort of bringing parallel civil charges for insider trading, say attorneys at Dentons. 
- 
								
								Rising Enforcement Stakes For Pharma Telehealth Platforms.jpg)  Two pieces of legislation recently introduced in Congress could transform the structure and promotion of telehealth arrangements as legislators increasingly scrutinize direct-to-consumer advertising platforms, potentially paving the way for a new U.S. Food and Drug Administration policy with bipartisan support, say attorneys at Sheppard Mullin. 
- 
								Series Law School's Missed Lessons: Communicating With Clients  Law school curricula often overlook client communication procedures, and those who actively teach this crucial facet of the practice can create exceptional client satisfaction and success, says Patrick Hanson at Wiggam Law. 
- 
								
								3 Judicial Approaches To Applying Loper Bright, 1 Year Later  In the year since the U.S. Supreme Court overturned Chevron deference in its Loper Bright Enterprises v. Raimondo decision, a few patterns have emerged in lower courts’ application of the precedent to determine whether agency actions are lawful, say attorneys at Husch Blackwell. 
- 
								
								Prepping For SEC's Changing Life Sciences Enforcement.jpg)  By proactively addressing several risk areas, companies in the life sciences sector can position themselves to minimize potential exposure under the U.S. Securities and Exchange Commission's return to back-to-basics enforcement focused on insider trading and fraud, say attorneys at Morgan Lewis. 
- 
								Series Adapting To Private Practice: From US Rep. To Boutique Firm  My transition from serving as a member of Congress to becoming a partner at a boutique firm has been remarkably smooth, in part because I never stopped exercising my legal muscles, maintained relationships with my former colleagues and set the right tone at the outset, says Mondaire Jones at Friedman Kaplan. 
- 
								
								How Providers Can Brace For Drug Pricing Policy Changes.jpg)  Though it's uncertain which provisions of the Trump administration's executive order aimed at addressing prescription drug costs will eventually be implemented, stakeholders can reduce potential negative outcomes by understanding pathways that could be used to effectuate the order's directives, say attorneys at McDermott. 
- 
								
								Discretionary Denial Rulings May Spur Calls For PTAB Reform  The U.S. Patent and Trademark Office's recent decision in iRhythm Technologies v. Welch Allyn, denying inter partes review based on the patent owner's settled expectations that the patent would not be challenged, could motivate patent holders to seek Patent Trial and Appeal Board reform to preserve patent quality without burdening owners, say attorneys at Dechert. 
- 
								
								Comparing New Neural Data Privacy Laws In 4 States  Although no federal law yet addresses neural privacy comprehensively, the combined effect of recent state laws in Colorado, California, Montana and Connecticut is already shaping the regulatory future, but a multistate compliance strategy has quickly become a gating item for those experimenting with neuro-enabled workplace tools, says Kristen Mathews at Cooley. 
- 
								
								Spinoff Transaction Considerations For Biotech M&A  Amid current market challenges, boards and management teams of biotech companies can consider several strategies for maximizing value should a spinoff opportunity arise, but not without significant advance planning and careful implementation, particularly in cases that might qualify as tax-free, say attorneys at Paul Hastings. 
- 
								Opinion Senate's 41% Litigation Finance Tax Would Hurt Legal System  The Senate’s latest version of the Big Beautiful Bill Act would impose a 41% tax on the litigation finance industry, but the tax is totally disconnected from the concerns it purports to address, and it would set the country back to a time when small plaintiffs had little recourse against big defendants, says Anthony Sebok at Cardozo School of Law. 
- 
								
								Psychedelic Treatment Regs May Be At A Tipping Point  Recent scientific and public attention suggest that development of psychedelics as treatment for some conditions may be at a tipping point, which could bring on more rapid change and opportunities for stakeholders who may in the future benefit from greater access to safe and effective psychedelic medicines, say attorneys at King & Spalding.